PHF14 and cancer: As shown in Figures 4C–H, in BRCA and CESC cancer patients, the PHF14-unaltered group exhibited a favourable prognosis for DSS (disease-specific survival) (P-values were 1.55e-9 and 1.143e-3, respectively), OS (P-values were 6.087e-6 and 5.968e-5, respectively) and PFS (P-values were 1.191e-6 and 0.0141, respectively) as compared to the PHF14-altered group.